Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 15;9:68. doi: 10.1038/s41523-023-00568-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Crown 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, c, e Growth and survival curves of AT3, 4T1ch9 and AT3OVA tumours. Tumour-bearing mice were treated with vehicle, olaparib and/or AZD1775. 6 mice per treatment group. Data shows mean tumour volume ± s.d. b, d AT3 tumour-bearing mice were treated with vehicle, olaparib and/or AZD1775 for 15 days. Tumours and were harvested and analysed via flow cytometry. 10 mice per treatment group. Data shows mean ± s.d. f AT3OVA tumour-bearing mice were treated with vehicle, olaparib and/or AZD1775 for 16 days. PD-L1 expression on AT3OVA tumours was acquired at 8 days of treatment. All other markers were acquired at 16 days of treatment. 6 mice per treatment group. Data pooled from 3 independent experiments. Data shows mean ± s.d. ns: non-significant. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA for FACS analyses, two-way ANOVA for tumour growth curves and log-rank (Mantel-Cox) test for survival curves.